logo
William J. Rutter, Biotech Pioneer of Gene-Based Medicine, Dies at 97

William J. Rutter, Biotech Pioneer of Gene-Based Medicine, Dies at 97

New York Times15 hours ago
William J. Rutter, a scientist who helped create the modern biotechnology industry as a founder of a company that turned breakthroughs from academic labs into commercial medicines, including the first genetically engineered vaccine and a therapy for multiple sclerosis, died on July 11 at his home in San Francisco. He was 97.
His daughter, Cindy Rutter, said the cause was complications of urothelial carcinoma, a cancer of the urinary system.
In 1981, Dr. Rutter and two University of California colleagues founded the Chiron Corporation in Emeryville, Calif. Along with the South San Francisco start-up Genentech, it established the Bay Area as the country's biotech capital, a counterpart to the computing boom in Silicon Valley.
Chiron specialized in recombinant DNA technology, also known as gene splicing — the technique of snipping a gene from one organism and inserting it into the DNA of another organism.
In 1968 Dr. Rutter, a biochemist, was recruited by the University of California, San Francisco, to help transform it into a research powerhouse with funding from the National Institutes of Health. He helped pioneer the science of genetic engineering — a foundation of the biotech industry that set it apart from traditional pharmaceutical development.
He started Chiron (pronounced KY-ron) with Pablo D. T. Valenzuela, a fellow biochemist at U.C.S.F., and Edward E. Penhoet, a professor at the University of California, Berkeley; Dr. Rutter was chairman of the board. The company was named for a centaur in Greek mythology known for his skill in the healing arts
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Remember Ingenuity? NASA's proposed Skyfall mission takes it further in stunning video
Remember Ingenuity? NASA's proposed Skyfall mission takes it further in stunning video

Digital Trends

timea few seconds ago

  • Digital Trends

Remember Ingenuity? NASA's proposed Skyfall mission takes it further in stunning video

NASA's incredible Ingenuity helicopter spent nearly three flying across the surface of Mars, becoming the first aircraft to achieve powered, controlled flight on a planet other than Earth. After suffering damage to one of its blades in early 2024, Ingenuity was grounded for good, and now rests on the martian surface as a testament to technological innovation and the triumph of autonomous flight on another planet. In an exciting development, the plucky helicopter has now inspired Skyfall, a mission concept recently unveiled by Virginia-based AeroVironment (AV) and NASA's Jet Propulsion Laboratory (JPL), who worked together to develop the Ingenuity aircraft. As you can see in the video at the top of this page, the Skyfall mission is designed to deploy not one but six helicopters on Mars, each of which would fly off to explore various locations selected by NASA as potential landing spots for the first crewed mission to the red planet, which could take place in the 2030s. The gathered data could also help scientists learn more about Mars, contributing to the expanding database of information collected by other Mars vehicles such as the Perseverance and Curiosity rovers. The video shows the dramatic Skyfall Maneuver, described by AV as 'an innovative entry, descent, and landing technique whereby the six rotorcraft deploy from their entry capsule during its descent through the martian atmosphere.' With the helicopters flying down to the Mars surface under their own power, the Skyfall system would do away with the need for a landing platform, which is one of the most expensive parts of any Mars mission and also carries huge risk. Just like Ingenuity, each helicopter would be capable of operating autonomously, and beam high-resolution imagery back to Earth for analysis, allowing mission planners to select the best possible landing location for the first human mission. 'Skyfall offers a revolutionary new approach to Mars exploration that is faster and more affordable than anything that's come before it,' said William Pomerantz, head of space ventures at AV. 'Thanks to a true partnership between industry and government, we're expanding the unprecedented success of Ingenuity.' Pomerantz added that with six helicopters, 'Skyfall offers a low-cost solution that multiplies the range we would cover, the data we would collect, and the scientific research we would conduct, making humanity's first footprints on Mars meaningfully closer.' With NASA's first human missions in mind and the need to identify an ideal landing area, AV is already working with NASA's JPL in the hope of getting the green light for the mission before working toward a potential 2028 launch.

Claims Data Fail to Accurately Identify MI Types
Claims Data Fail to Accurately Identify MI Types

Medscape

timea few seconds ago

  • Medscape

Claims Data Fail to Accurately Identify MI Types

TOPLINE: Clinical auditing reveals significant misclassification in administrative codes for myocardial infarction (MI), with only 39% of type 1 (T1MI) codes and 72% of type 2 (T2MI) codes for the condition accurately reflecting the true diagnosis, researchers found. Nearly half of patients coded for T1MI had T2MI, whereas 26% of T2MI codes represented myocardial injury. METHODOLOGY: Researchers identified 350 randomly sampled patients with T1MI codes and 350 patients with T2MI codes during inpatient encounters using the International Statistical Classification of Diseases and Related Health Problems-10th Revision. The analysis included patients aged 65 years and older from October 1, 2017, to May 9, 2024, within eight hospitals in the Mass General Brigham system. Using the 4th Universal Definition of MI, the researchers reviewed the clinical encounters to assess evidence of plaque erosion or thrombus vs oxygen demand-supply imbalance. A second physician review was conducted for 146 challenging and 146 nonchallenging cases. TAKEAWAY: Among the 350 patients coded as having had T1MI, clinical adjudication revealed 138 (39%) as correctly diagnosed; 159 (45%) in fact had T2MI, and 35 (10%) had myocardial injury. Of the 350 patients coded as having had T2MI, 251 (72%) were confirmed, four (1%) were found to have T1MI, and 91 (26%) had myocardial injury. A second physician review demonstrated a high degree of agreement with the initial review, with a 94% agreement in nonchallenging cases and 86% in challenging cases. Hospitals equipped with vs without cardiac catheterization laboratories showed significantly lower misclassification rates (43% vs 58%; P = .0298). IN PRACTICE: 'Among individuals assigned a T1MI claims code, nearly one half have T2MI and many others have myocardial injury; fewer than one half have true T1MI,' the researchers reported. 'Our results also confirm and extend previous work showing that among those with T2MI codes, slightly more than one half have true T2MI, with most of the misclassification related to myocardial injury rather than T1MI. This has critically important implications for epidemiology and public policy' related to acute myocardial infarction. SOURCE: The study was led by Andrea Martinez, MD, of the Department of Medicine at Massachusetts General Hospital, Boston. It was published online on July 21 in Journal of the American College of Cardiology. LIMITATIONS: The results may not be generalized to other hospital systems and countries, where patterns of misclassification might differ. The researchers noted external validity assessment across multiple healthcare systems and in countries that have already introduced International Classification of Diseases-11th revision coding would be beneficial. While patterns of misclassification might have changed over time, the analysis was intentionally restricted to the period when codes for both T1MI and T2MI were available. DISCLOSURES: The study received support through a grant to Jason Wasfy from the Massachusetts General Hospital Executive Committee on Research. Individual authors reported receiving other grants and support, including grants from industry. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The Knowledge Society (TKS) Dubai Edition is Now Accepting Applications for September 2025 Cohort – Apply by July 31, 2025
The Knowledge Society (TKS) Dubai Edition is Now Accepting Applications for September 2025 Cohort – Apply by July 31, 2025

Entrepreneur

timea few seconds ago

  • Entrepreneur

The Knowledge Society (TKS) Dubai Edition is Now Accepting Applications for September 2025 Cohort – Apply by July 31, 2025

The Knowledge Society (TKS) – Dubai Edition is a 10-month innovation program that focuses on emerging fields like AI, biotechnology, space, nanotechnology, and more. You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. Dubai Future Foundation and The Knowledge Society (TKS) are now accepting applications for you TKS Dubai, an innovation program designed to equip high-potential students (ages 13–17) with the skills, knowledge, and mindset needed to thrive in a rapidly evolving world. The Knowledge Society (TKS) – Dubai Edition is a 10-month innovation program that focuses on emerging fields like AI, biotechnology, space, nanotechnology, and more. It provides cutting-edge knowledge in fields such as artificial intelligence, robotics, and biotechnology — all while connecting students to a global network of mentors, industry leaders, and future-focused thinkers. In partnership with Dubai Future Foundation, TKS offers up to 30 full scholarships for UAE nationals and merit/need‑based aid for others.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store